Valbenazine Will Be Used to Reduce Tardive Dyskinesia Symptoms

June 2017

Valbenazine (Ingrezza, in-GREH-zah) will be the first med approved to treat tardive dyskinesia.

Up to 30% of patients on long-term antipsychotics develop tardive dyskinesia...involuntary lip smacking, facial grimaces, etc.

It's usually associated with higher doses, longer durations, and higher-potency typical antipsychotics, such as haloperidol.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Antibiotics Consider Cefazolin as a First-Line Option for MSSA Bacteremia
Critical Care Take Precautions if Push-Dose Pressors Are Used at Your Hospital
Anemia Be Aware of Changes in the Erythropoiesis-Stimulating Agent REMS Program
Acute Pain Dispel the Myth That Ketorolac Is a Stronger NSAID
Antithrombotics Investigate Low Doses of Direct Oral Anticoagulants
Inhalers Ensure Safe Transitions of Care With Ellipta Rxs
Psychiatry Be Aware of Nuedexta's Off-Label Use
Opioids Avoid Codeine and Tramadol in Kids and Breastfeeding Women
New Drugs Valbenazine Will Be Used to Reduce Tardive Dyskinesia Symptoms
Fibromyalgia Encourage Nondrug Measures to Help Fibromyalgia Patients